funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. Called NGoXIM, the vaccine is based on gonococcal OMVs combined with ...

Initial clinical trials compared two vaccine formulations, both containing 50 µg each of fHbp, NadA allele 3 and NHBA. Both also contained OMV, one from the Norwegian outbreak strain and the ...

Several studies have explored the effectiveness of meningococcal vaccines, specifically the outer membrane vesicle (OMV) vaccines, in preventing gonorrhea. One retrospective observational study ...